Bosentan (under the brand name Tracleer by Actelion Pharmaceuticals) is the first approved endothelian receptor antagonist. It was approved by the FDA in November 2001 and is used in the treatment of Pulmonary Arterial Hypertension.
MedlinePlus: Bosentan
Provides information on usage, precautions, side effects and brand names when available. Data provided by government agencies and health-related organizations
Tracleer
Features an overview of pulmonary hypertension, prescribing information for US residents, and press releases.
Bosentan Therapy for Pulmonary Arterial Hypertension
Actelion's slide show presentation to the FDA. (August 15, 2001)
[Sunflower Mozilla]
Last update:
October 17, 2016 at 2:37:04 UTC
Health
Home
News
Recreation
Reference
Regional
Science
Shopping
Society
Sports
All Languages
Arts
Business
Computers
Games